期刊
ANTIOXIDANTS
卷 10, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/antiox10040513
关键词
phenolic compound; tracheloside; anti-oxidant; apoptosis; EMT; metastasis; colorectal cancer
资金
- National Research Foundation of Korea (NRF) - Korean government [NRF-2018R1D1A1B07050357]
Recent research has shown that tracheloside (TCS) can inhibit the proliferation of colorectal cancer (CRC) cells and induce cell cycle arrest and apoptosis through its antioxidant properties. In addition, TCS was found to inhibit the metastasis of CT26 cells, suggesting it may be a novel therapeutic agent for inhibiting metastatic phenotypes of murine CRC cells.
Recent research suggests a relationship between cancer progression and oxidative mechanisms. Among the phenolic compounds such as tracheloside (TCS) are a major bioactive compound that can combat oxidant stress-related chronic diseases and that also displays anti-tumor activity. Although TCS can inhibit mammalian carcinoma, its effects on colorectal cancer (CRC) have not been clarified. The purpose of this study was to investigate the effects of TCS on the proliferation of CRC cells, the metastasis of CT26 cells, and the molecular mechanisms related to TCS in vitro and in vivo. A cell viability assay showed that TCS inhibited the proliferation of CRC cells. TCS-treated CT26 cells were associated with the upregulation of p16 as well as the downregulation of cyclin D1 and CDK4 in cell cycle arrest. In addition, TCS induced apoptosis of CT26 cells through mitochondria-mediated apoptosis and regulation of the Bcl-2 family. Expression of epithelial-mesenchymal transition (EMT) markers was regulated by TCS treatment in CT26 cells. TCS significantly inhibited the lung metastasis of CT26 cells in a mouse model. These results suggest that TCS, by inducing cell cycle arrest and apoptosis through its anti-oxidant properties, is a novel therapeutic agent that inhibits metastatic phenotypes of murine CRC cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据